Literature DB >> 1514162

Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas.

K Satake1, H Nishiwaki, H Yokomatsu, Y Kawazoe, K Kim, A Haku, K Umeyama, I Miyazaki.   

Abstract

The prognosis of 185 patients who underwent surgical resection of small carcinomas of less than 2.0 centimeters (T1) of the pancreas in whom either standard or extended resection was used was analyzed. Pancreatic resection was performed upon 98.3 percent of the patients who were more than 49 years old. The location of the tumor was the head of the pancreas in 83.4 percent of the patients, the body of the pancreas in 13.2 percent and the tail of the pancreas in 3.3 percent. Tumor staging revealed 42.9 percent in stage I and the remainder in advanced stage, that is 33.1 percent stage II, 18.8 percent stage III and 5.1 percent stage IV. When standard resection was performed, surgical cure rates were more than 80 percent in stage I, II and III, but in stage IV, it was only 16.6 percent. After extended resection, the surgical cure rates increased even in stage IV (100 percent). There were no significant differences in the overall postoperative cumulative survival rates between standard and extended operation. In stage II, however, a significant better survival rate was observed after extended resection than after standard resection.

Entities:  

Mesh:

Year:  1992        PMID: 1514162

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  30 in total

Review 1.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.

Authors:  W Meyer; C Jurowich; M Reichel; B Steinhäuser; P H Wünsch; C Gebhardt
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

3.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 4.  The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence.

Authors:  Michael B Farnell; Gerard V Aranha; Yuji Nimura; Fabrizio Michelassi
Journal:  J Gastrointest Surg       Date:  2007-12-18       Impact factor: 3.452

5.  Extended resection for pancreatic adenocarcinoma.

Authors:  T M van Gulik; A Nakao; H Obertop
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

6.  Does extended pancreaticoduodenectomy increase operative morbidity and mortality vs. standard pancreaticoduodenectomy?

Authors:  C Iacono; L Bortolasi; E Facci; G Falezza; G Prati; G Mangiante; G Serio
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

Review 7.  Eat your cereal.

Authors:  B Gardner
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 8.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

9.  Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?

Authors:  L E Harrison; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

10.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.